On May 22, 2021, the sky is clear, the weather is clear, and the wind is breezy. The 7th Academic Annual Meeting of the Hematology Branch of the Chinese Association of Traditional Chinese Medicine was grandly held in Hangzhou, an international metropolis known as "Three Faces of Clouds and Mountains and One Side of the City".

As one of the co-organizers of this conference, Mengyang Pharmaceuticals invited clinical experts from all over the country who are committed to multidisciplinary development of tumors and blood to gather in Hangzhou, and held the "Implementation Forum of Traditional Chinese Medicine Diagnosis and Treatment Programs for Blood Diseases" at the conference. And officially launched the project of "Shengbai Oral Liquid Prevention and Treatment of Leukopenia After Chemotherapy Observation Cases Collection".

The chairman of the conference, Professor Chen Xinyi, chairman of the Hematology Branch of the Chinese Association of Traditional Chinese Medicine, delivered a speech for this sub-forum. He pointed out that in order to better promote and apply the "diagnosis and treatment plan and path interpretation of the dominant diseases of blood diseases treated by traditional Chinese medicine" and meet the needs of clinical diagnosis and treatment, in 2021, the Blood Disease Branch of the Chinese Association of Traditional Chinese Medicine will start the training work and research topics of path interpretation funding projects. The convening of this sub-forum of Mengyang Pharmaceutical has played a very good role model and made a good start for the reasonable and compliant work of the sub-committee. Here, I would like to express my heartfelt thanks. We also welcome more insightful people to join our blood disease branch, and work together to do a better job in the prevention and treatment of tumors and tumor complications.

Then, Mr. Zhang Min, chairman of Mengyang Pharmaceutical, delivered a speech for the conference. He introduced the corporate positioning, development status and future planning of Mengyang Pharmaceutical, and wished the conference a complete success.

In the academic exchange part, Professor Tian Shaodan from Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine brought a wonderful sharing of "Interpretation of Diagnosis and Treatment Plans and Paths for Predominant Diseases of Blood Diseases Treated by Traditional Chinese Medicine" to the participating experts. 52 experts co-edited, involving a total of 19 common diseases and symptoms of the blood system. She pointed out that the occurrence, progression or evolution of blood diseases is mainly based on deficiency syndrome, and there are more than 40 Chinese patent medicines for treatment that are currently on the market. Among them, there are not many Chinese patent medicines that correspond to prescriptions and syndromes, medicines and syndromes, and medicines and diseases, and there are not many Chinese patent medicines that have a win-win effect. In this regard, she focused on introducing the new Chinese medicine "Shengbai Oral Liquid", which has the highest frequency of expert recommendation and evidence-based medical evidence. It is evaluated as a new traditional Chinese medicine that can quickly invigorate the kidney and generate marrow and actively generate whitening in domestic clinical promotion.

Subsequently, Professor Sun Tao from Dongfang Hospital of Beijing University of Traditional Chinese Medicine gave a report on "Re-evaluation of Shengbai Oral Liquid after its launch and sharing of multi-center clinical research results". Studies have confirmed that Shengbai Oral Liquid can effectively reduce the incidence of neutropenia, especially the incidence of grade I and II neutropenia and leukopenia. In addition, it also has certain advantages in reducing the incidence of peripheral blood thrombocytopenia. The sub-items of the TCM symptom scale - numbness, polyuria, lethargy, forgetfulness, fatigue (weakness), sadness, sputum, fear of cold - the experimental group was significantly better than the control group, indicating that Shengbai Oral Liquid has certain advantages in improving symptoms . In terms of fatigue improvement, the improvement of overall fatigue and fatigue sub-items of the test group was significantly better than that of the control group, indicating that Shengbai Oral Liquid has a good effect on improving fatigue symptoms. Through the analysis of vital signs, physical examination, laboratory examination, electrocardiogram, combined medication and adverse events, it shows that Shengbai Oral Liquid has good safety in clinical application. Professor Sun Tao also pointed out that the culture of traditional Chinese medicine has a long history and is extensive and profound. While inheriting the essence, Shengbai Oral Liquid is also making continuous progress.

Then, Project Consultant Professor Chen Xinyi, Project PI Professor Sun Tao, and Ms. Liu Limin, Vice President of Marketing of Mengyang Pharmaceutical Co., Ltd. jointly took the stage to officially launch the project. A climax was ushered in with warm applause.

Finally, Ms. Liu Yu, the product manager of Mengyang Pharmaceutical, gave a detailed project interpretation for everyone. So far, the forum on the implementation of TCM diagnosis and treatment schemes for blood diseases has come to a successful conclusion.

The convening of this forum is not only a feast of academic exchanges, but also a new journey of multidisciplinary joint prevention and treatment of tumors. It is also the mission of Mengyang Pharmaceutical to improve the quality of life of cancer patients, adhere to the patient-centered approach, and focus on unmet clinical needs. Oriented, keep upright and innovate, and continue to strive for a big step forward!